Renal Cell Carcinoma Trial Design Patterns

Definition

Renal cell carcinoma (RCC) encompasses clear cell RCC (~75%), papillary RCC (~15%), chromophobe, and rare subtypes. Phase 3 RCC trials are stratified by: IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) risk group (favorable vs. intermediate/poor risk), prior lines of therapy, histology (clear cell vs. non-clear cell), and PD-L1 expression in IO trials. The treatment landscape has shifted dramatically from VEGF TKIs (sunitinib, pazopanib) to IO + VEGF TKI combinations (pembrolizumab+axitinib, nivolumab+cabozantinib, pembrolizumab+lenvatinib) and IO + IO combinations (nivolumab+ipilimumab in intermediate/poor risk).

CTG Phase 3 RCC dataset (112 trials): PFS primary ~40/112 (36%), OS primary ~25/112 (22%), DFS/RFS ~10/112 (9%). Median enrollment 456 patients.

Regulatory Position

Metastatic RCC: PFS + OS co-primary is increasingly the standard for IO combination trials. The FDA has accepted PFS as primary for regular approval when the HR is large (≤ 0.65) and OS is trending supportively. For adjuvant RCC, DFS is the accepted primary endpoint (pembrolizumab KEYNOTE-564).

Adjuvant RCC: DFS primary following nephrectomy for high-risk disease. Sunitinib adjuvant (S-TRAC): DFS HR 0.76 (primary analysis, FDA approved); pembrolizumab KEYNOTE-564: DFS HR 0.68 (approved 2021).

Status: FDA Cancer Endpoints 2018 = Final

When to Use Each Endpoint

Setting	Primary Endpoint	Key Secondary	Notes
1L metastatic (IO + VEGF TKI)	OS + PFS co-primary	ORR	KEYNOTE-426 (pembro+axitinib); CheckMate 9ER (nivo+cabo); CLEAR (pembro+lenva)
1L metastatic (IO + IO, int/poor risk)	OS	PFS, ORR	CHECKMATE-214 (nivo+ipi, OS HR 0.63 int/poor risk)
1L metastatic (VEGF TKI era)	PFS	OS	COMPARZ (sunitinib vs. pazopanib, PFS HR 1.05 — NI)
2L post-VEGF TKI (IO)	OS	PFS, ORR	CHECKMATE-025 (nivo vs everolimus, OS HR 0.73)
2L post-IO (VEGF TKI or TKI+IO)	PFS	OS	CONTACT-03, LITESPARK-005
Adjuvant (high-risk post-nephrectomy)	DFS	OS	KEYNOTE-564 (pembro, DFS HR 0.68); S-TRAC (sunitinib, DFS HR 0.76)
Non-clear cell metastatic	OS or PFS	ORR	Fewer Phase 3 data; often basket or histology-specific

Design Considerations

PFS + OS Co-Primary (IO Combination Standard)

The modern IO+VEGF TKI Phase 3 design uses co-primary endpoints:

Both PFS and OS must be significant for the trial to fully succeed (or a pre-specified hierarchical order)
Alpha allocation: OS and PFS each at α = 0.025 (two-sided), or hierarchical (OS tested first, then PFS, or vice versa)
Power: Each endpoint must be independently powered (joint power ≈ 80% if correlation is high)

KEYNOTE-426 design:

Co-primary: OS (α = 0.025) + PFS by IRC (α = 0.025)
Power: 80% for each; ~856 patients
Result: PFS HR 0.69 (p<0.001); OS HR 0.53 at 12-month analysis → regular approval

High Crossover Rates (RCC-Specific Challenge)

RCC has some of the highest crossover rates in oncology. In 2L IO trials where control arm receives VEGF TKI, patients often cross to IO after progression:

Treatment policy (primary): All deaths counted regardless of subsequent IO therapy
IPCW sensitivity: Adjust OS for informative censoring when patients cross to active IO — significant in CHECKMATE-025 context
SAP language: "A pre-specified sensitivity analysis using IPCW will estimate overall survival adjusted for subsequent immunotherapy receipt in the control arm."

IMDC Risk Stratification

IMDC factors (Heng criteria) are mandatory stratification:

Favorable risk: 0 IMDC factors (PS 0, Hgb ≥ LLN, calcium normal, time <1 year from diagnosis to treatment, neutrophils < ULN, platelets < ULN)
Intermediate/poor risk: 1–6 IMDC factors
IO+IO combination (nivo+ipi) primarily benefits intermediate/poor risk patients; favorable risk patients may not benefit

Intercurrent Events

Subsequent Anti-RCC Therapy (Multiple Active Lines)

OS: Treatment policy — sequential VEGF TKI → IO → VEGF TKI (3+ active lines) makes hypothetical OS impractical
PFS: Hypothetical or treatment policy depending on protocol — varies across trials
CHECKMATE-025: PFS not primary (OS primary); treatment policy for OS

Dose Modifications (VEGF TKI — Universal)

Sunitinib, axitinib, cabozantinib, lenvatinib require dose adjustments in >50% of patients. Treatment policy mandatory — dose reductions are part of real-world drug use; events counted regardless.

Regulatory Precedent

Trial	Drug	Setting	Primary Endpoint	HR / Result	Approval
CHECKMATE-214	Nivo + ipi	1L int/poor risk	OS	HR 0.63 (int/poor risk)	Regular (2018)
KEYNOTE-426	Pembro + axitinib	1L all risk	OS + PFS co-primary	OS HR 0.53; PFS HR 0.69	Regular (2019)
CheckMate 9ER	Nivo + cabozantinib	1L	PFS + OS	PFS HR 0.51; OS HR 0.66	Regular (2021)
CLEAR	Pembro + lenvatinib	1L	PFS	HR 0.39	Regular (2021)
CHECKMATE-025	Nivolumab vs. everolimus	2L	OS	HR 0.73	Regular (2015)
KEYNOTE-564	Pembrolizumab adjuvant	Adjuvant high-risk	DFS	HR 0.68	Regular (2021)
S-TRAC	Sunitinib adjuvant	Adjuvant high-risk	DFS	HR 0.76	Regular (2017)

Limitations and Pitfalls

Non-proportional hazards in IO trials: IO combinations show delayed separation with PH violation. RMST pre-specified in modern trials. Cox HR underestimates eventual benefit when curves separate late.

Favorable risk patients: Nivo+ipi does not clearly benefit favorable risk patients (CHECKMATE-214). IO+VEGF TKI combinations show benefit across risk groups but magnitude varies. Trial designs must pre-specify IMDC subgroup analyses.

Non-clear cell histology evidence gap: Most Phase 3 approvals are in clear cell RCC. Non-clear cell RCC (papillary, chromophobe) are underrepresented in Phase 3 trials. Off-label use from clear cell approvals remains common but unvalidated.

Backlinks

Source: FDA Cancer Endpoints 2018 (Final) Compiled from FDA guidance + CTG Phase 3 RCC dataset (112 trials) + known Phase 3 trial results